CHANGE OF ANTICOAGULANT EFFECT OF RIVAROXABAN DURING A DAY
https://doi.org/10.24884/0042-4625-2015-174-4-77-79
Abstract
The article presents an assessment of anticoagulant effect of rivaroxaban in 35 patients with thromboembolic diseases. The results of expressed anticoagulant effect of rivaroxaban were obtained during a day (or more). The data of increase in sensitivity to thrombomodulin indicated about work enchancement of protein C system against the background of rivaroxaban therapy.
About the Authors
I. V. Gel’Tser
Russian research institute of hematology and transfusiology of Federal medicobiological agency of Russia
Russian Federation
Russian Federation
O. A. Smirnova
Russian research institute of hematology and transfusiology of Federal medicobiological agency of Russia
Russian Federation
Russian Federation
O. Yu. Matvienko
Russian research institute of hematology and transfusiology of Federal medicobiological agency of Russia
Russian Federation
Russian Federation
O. G. Golovina
Russian research institute of hematology and transfusiology of Federal medicobiological agency of Russia
Russian Federation
Russian Federation
L. P. Papayan
Russian research institute of hematology and transfusiology of Federal medicobiological agency of Russia
Russian Federation
Russian Federation
References
1. Баркаган З. С., Цывкина Л. П., Момот А. П. Ошибки, просчеты и пути совершенствования клинического применения низкомолекулярных гепаринов // Клин. фармакол. и тер. 2002. № 11. С. 1-5.
2. Наместников Ю. А. Диагностика гиперкоагуляции с помощью теста генерации тромбина: Дис. … канд. мед. наук. СПб., 2012. 52 с.
3. Arachchillage D. R. J., Efthymiou M., Mackie I. J. et al. Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism // Thromb. Res. 2014. № 11. Р. 1-6.
4. Beyer-Westendorf J., Ageno W. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism // Thromb. Haemost. 2015. № 113. Р. 231-246.
5. Brodmann M. Do novel oral anticoagulants do better than standard therapy in the treatment of deep vein thrombosis? // Haemostaseologie. 2013. № 33. Р. 218-224.
6. Mann K. G., Brummel K., Butenas. What is all that thrombin for? // Thromb. Haemost. 2003. № 7. Р. 1504-1514.
7. Samama M. M., Martinoli J. L., LeFlem L. et al. Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor // Thromb. Haemost. 2010. № 103. Р. 815-25.
8. Samama M. M., Mendell J., Guinet C. et al. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux // Thromb. Res. 2012. № 129. Р. 77-82.
Review
For citations:
Gel’Tser I.V., Smirnova O.A., Matvienko O.Yu., Golovina O.G., Papayan L.P. CHANGE OF ANTICOAGULANT EFFECT OF RIVAROXABAN DURING A DAY. Grekov's Bulletin of Surgery. 2015;174(4):77-79. (In Russ.) https://doi.org/10.24884/0042-4625-2015-174-4-77-79
Views:
425
Email this article 